Alzheimer Disease

With gastrointestinal-based adverse effectss for rivastigmine and other cholinesterase inhibitors, a weight of <50 and <55 kg respectively leads to an increased risk for toxicities.

Investigators analyzed the effects of harmful accumulation of HDAC6 in the brains of mouse models with Alzheimer disease to determine any changes in disease progression.

Investigators found that individuals who self-identified as Black were less frequently imaged for cognitive impairment with MRI and at an older age compared with White and Hispanic patients.

Investigators believe lowering cholesteryl ester levels could help prevent brain damage and behavioral changes, reducing the risk of Alzheimer disease.

Food insecurity was associated with an increased risk of dementia, poorer memory function, and faster memory decline in older adults.

Lisa Deschamps, CEO of AviadoBio, discusses frontotemporal dementia and AVB-101, a one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene and restoring progranulin levels in the brain.

The drug may be a risk factor for dementia-related illnesses.

In May 2023, the FDA approved brexpiprazole as the first and only drug to receive approval for treatment of agitation associated with Alzheimer Disease dementia.

Study also showed that 76% of individuals treated with lecanemab-irmb had no deterioration in the tau positron emission tomography (PET) subset.

A weekly dose of injectable lecanemab-irmb (Leqembi) could allow patients with Alzheimer disease to receive the drug at home instead of visiting an infusion center twice per month.

Approximately 96% physicians feel it is important to assess patients aged 60 years and older for cognitive impairment, but 48% of these patients have no had assessments from their physician.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody that targets amyloid plaques, which are thought to play a role in the development and progression of Alzheimer disease.

Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.

Maintaining a purpose in life has the potential to reduce apathy related to dementia and cognitive decline.

In clinical trials, lecanemab showed a reduction of amyloid beta plaque in patients with Alzheimer disease.

Testosterone may protect the brain against dementia pathology, but the association has not been proven.

Infections were associated with a 1.49-fold increase in the rate of dementia in both the short- and long-term rates, however, the increases were greater in the short term.

Symptoms of dementia can be difficult to differentiate from typical age-related behavior changes and other common and potentially curable conditions.

One IVIG product showed overall improvement in neuroprotection, including alleviating cognitive decline and ameliorating AB deposition in Alzheimer disease.

Heart health may influence long-term brain health as early as middle age.

This social determinant of health could have the same level of negative impact on health as the experience of racism, poverty, or low education.

UB-311 has shown to be well-tolerated with a durable antibody response in a previous phase 1 trial, and new results from a phase 2a study support its continued development.

Through previous literature, investigators found that intervention with nutritional supplements may help to improve cognitive performance and reduce the severity of memory impairment in adults with Alzheimer disease.

Advancements in the development of amyloid-targeting monoclonal antibodies show promise for treating Alzheimer disease, but there have been concerns around cost, adverse reactions, and inequity of care for marginalized patients.

Nikhil Palekar discusses the FDA approval of lecanemab-irmb (Leqembi, Eisai) and what this means for those who have Alzheimer Disease.